Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Altretamine→

Altretamine Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
645-05-6
Molecular formula
C9H18N6
Molecular weight
210.28 g/mol
Drug class
Antineoplastic alkylating-like cytotoxic agenthexamethylmelamine derivative
Mechanism of action
The precise antitumour mechanism is not fully elucidated. Altretamine is a cytotoxic alkylating-like agent; metabolic activation and DNA damage are thought to contribute to inhibition of tumour-cell proliferation. The detailed mechanism should be described as incompletely established.
Indications / reported uses
  • Palliative treatment of persistent or recurrent ovarian cancer after failure of a first-line cisplatin- and/or alkylating-agent-based combination regimen in the specific US product indication

Sources: US DailyMed — Altretamine capsules · NCI Drug Dictionary — Altretamine · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Altretamine Environmental Risk Assessment (ERA) (the Altretamine ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.